Evidence-Based Summary
Tesamorelin and ipamorelin both increase endogenous growth hormone secretion from the anterior pituitary somatotrophs, but they act via completely different receptor systems with differing regulatory standing and clinical validation. Tesamorelin (Egrifta) is a 44-amino-acid synthetic analogue of human growth hormone-releasing hormone (GHRH) capped with a trans-3-hexenoyl group. It binds specifically to somatotroph GHRH receptors, activating adenylate cyclase and cAMP signaling. Tesamorelin is FDA-approved (NDA 022505) for reducing visceral adipose tissue in HIV-associated lipodystrophy, validated across rigorous multicenter Phase 3 clinical trials that demonstrated significant visceral fat reduction and lipid improvement while preserving physiological feedback. In contrast, ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that bypasses the GHRH pathway altogether, acting instead on the growth hormone secretagogue receptor 1a (GHSR-1a), the native receptor for ghrelin. Ipamorelin triggers intracellular inositol triphosphate (IP3)/calcium mobilization to release rapid, episodic pulses of GH. While ipamorelin was engineered to be highly selective (avoiding the cortisol and prolactin spikes seen with older secretagogues like GHRP-6), it never received FDA or EMA approval, lacks Phase 3 human clinical trial evidence, and is prohibited at all times in competitive sports by WADA under Section S2.
Quick Comparison: Tesamorelin vs Ipamorelin
A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| Primary receptor target | GHRH receptor (Somatotroph Class B GPCR) | GHSR-1a / Ghrelin receptor (Class A GPCR) |
| Intracellular signaling | Gαs protein → adenylate cyclase → cAMP elevation | Gαq protein → PLC → IP3/DAG → intracellular Ca2+ surge |
| Peptide size & sequence | 44 amino acids (trans-3-hexenoyl-GHRH) | 5 amino acids (synthetic pentapeptide) |
| FDA regulatory status | FDA-approved prescription medicine (Egrifta) | Unapproved experimental research peptide |
| Phase 3 clinical trial evidence | Extensive Phase 3 RCTs in >800 human subjects | Zero completed Phase 3 clinical trials |
| Visceral fat reduction | Clinically proven (-15% to -18% reduction) | Studied only in rodent and preclinical models |
| Cortisol / Prolactin elevation | None (Selective GHRH action) | Minimal to none (Highly selective for GHSR-1a) |
| WADA Prohibited status | Prohibited at all times (Section S2) | Prohibited at all times (Section S2) |
GHRH Receptor (cAMP) vs Ghrelin Receptor (Calcium Influx)
The anterior pituitary gland regulates GH secretion through two distinct receptor families.
Tesamorelin: GHRH Receptor Adenylate Cyclase Activation
Primary Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)
Affinity Profile: Native-like high affinity for human GHRHR
Tesamorelin binds to GHRHR on the somatotroph membrane, activating Gαs protein and adenylate cyclase. Rising intracellular cAMP activates protein kinase A (PKA), which phosphorylates CREB, stimulating transcription of the growth hormone gene and promoting pulsatile exocytosis of stored GH granules. This pathway remains fully subject to endogenous somatostatin inhibition.
Ipamorelin: GHSR-1a Inositol Triphosphate Activation
Primary Targets: Growth Hormone Secretagogue Receptor 1a (GHSR-1a)
Affinity Profile: High selectivity and affinity for GHSR-1a (EC50 ~1.3 nM)
Ipamorelin mimics ghrelin by binding GHSR-1a, coupling to Gαq protein to activate phospholipase C (PLC). PLC cleaves PIP2 into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C, producing an immediate burst of GH exocytosis.
Approved Medicine vs Unapproved Research Peptide
Tesamorelin has an established pharmaceutical manufacturing and quality oversight chain.
Tesamorelin Status & Formulations
Egrifta (Tesamorelin SC)
Approval History: 2010 (NDA 022505)
Approved Indications: Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Ipamorelin Status & Formulations
Not approved by the FDA or EMA for human clinical use.
Critical Regulatory Distinction
Ipamorelin underwent early Phase 1 and Phase 2a clinical trials by Novo Nordisk and Helsinn for postoperative ileus, but was discontinued. It is unapproved for human medical use by the FDA and EMA.
Phase 3 Visceral Fat RCTs vs Early Secretagogue Trials
Comparing registrational trial data with early pilot investigations.
Tesamorelin: Tesamorelin Clinical Evidence
In two registrational Phase 3 trials (Falutz et al., NEJM 2007; J Clin Endocrinol Metab 2010), tesamorelin produced statistically significant 15% to 18% reductions in visceral adipose tissue assessed by CT scan, alongside improvements in triglycerides and cholesterol ratios.
Ipamorelin: Ipamorelin Clinical Evidence
In early Phase 1 healthy volunteer studies (Gobburu et al., Pharm Res 1999), ipamorelin caused dose-dependent increases in plasma GH peaking at ~45 minutes. A Phase 2 trial for postoperative ileus failed to demonstrate sufficient clinical benefit, and no human trials have verified long-term fat loss or body composition efficacy.
Comparative Tolerability & Risk Profile
Endocrine secretagogues require monitoring for glucose intolerance and fluid retention.
| Safety Consideration | Tesamorelin | Ipamorelin |
|---|---|---|
| Injection site reactions | Reported in ~25-35% of clinical trial patients | Erythema, swelling (unregulated research vial risks) |
| Appetite stimulation | Neutral (does not stimulate ghrelin appetite centers) | Minimal (engineered to avoid native ghrelin hunger surges) |
| Cortisol & Prolactin impact | No effect | No clinically significant elevation in Phase 1 trials |
| Fluid retention & carpel tunnel | Dose-dependent GH effect; observed in trials | Reported in anecdotal secretagogue use |
What Tesamorelin and Ipamorelin Have in Common
Where the two compounds overlap in biology, evidence or regulatory context.
Pituitary GH Stimulation
Both peptides stimulate anterior pituitary somatotrophs to release endogenous growth hormone.
Minimal Cortisol Spikes
Neither molecule triggers the significant ACTH or cortisol surges seen with older GHRPs.
Key Scientific & Clinical Differences
Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.
Receptor Target
Tesamorelin acts on the GHRH receptor; ipamorelin acts on the GHSR-1a (ghrelin) receptor.
Regulatory Standing
Tesamorelin is an FDA-approved medicine; ipamorelin is an unapproved research compound.
Human Body Composition Data
Tesamorelin is validated by Phase 3 CT-scan imaging; ipamorelin lacks controlled human efficacy data.
Scientific Comparison vs Clinical Recommendations
Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.
Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.
Approved Uses vs Online Claims
A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.
Stacking ipamorelin and tesamorelin doubles GH release safely
insufficientUnapproved off-label combination with zero controlled safety trials.
While GHRH and GHSR agonists act synergistically in isolated cell assays, combined unmonitored use risks excessive IGF-1 elevation, insulin resistance, and fluid retention without medical supervision.
Evidence Strength Across Clinical Domains
Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.
Endogenous GH Secretion
Both peptides proven to stimulate acute GH release in humans.
Visceral Adipose Reduction
Tesamorelin validated in Phase 3 trials; ipamorelin lacks human proof.
What Research Still Doesn’t Tell Us
Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.
Synergistic Secretagogue Dosing in Sarcopenia
Rigorous placebo-controlled trials evaluating whether combined GHRH/GHSR secretagogues can treat age-related muscle wasting safely.
Related Compound Profiles
Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.
Related Educational Resources
Scientific & Regulatory References
Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.
-
Peer-Reviewed RCT
Effects of a growth hormone-releasing factor analog on body composition in patients with HIV-associated lipodystrophy
-
Preclinical Pharmacology
Ipamorelin, the first selective growth hormone secretagogue